Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease

2006 | journal article; research paper. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease​
Meuer, K. ; Pitzer, C.; Teismann, P.; Krüger, C.; Göricke, B.; Laage, R. & Lingor, P.  et al.​ (2006) 
Journal of Neurochemistry97(3) pp. 675​-686​.​ DOI: 

Documents & Media


GRO License GRO License


Meuer, Katrin ; Pitzer, Claudia; Teismann, Peter; Krüger, Carola; Göricke, Bettina; Laage, Rico; Lingor, Paul ; Peters, Kerstin; Schlachetzki, Johannes C. M.; Kobayashi, Kazuto; Dietz, Gunnar P. H. ; Weber, Daniela; Ferger, Boris; Schäbitz, Wolf-Rüdiger; Bach, Alfred; Schulz, Jörg B. ; Bähr, Mathias ; Schneider, Armin; Weishaupt, Jochen H. 
We have recently shown that the hematopoietic Granulocyte-Colony Stimulating Factor (G-CSF) is neuroprotective in rodent stroke models, and that this action appears to be mediated via a neuronal G-CSF receptor. Here, we report that the G-CSF receptor is expressed in rodent dopaminergic substantia nigra neurons, suggesting that G-CSF might be neuroprotective for dopaminergic neurons and a candidate molecule for the treatment of Parkinson's disease. Thus, we investigated protective effects of G-CSF in 1-methyl-4-phenylpyridinium (MPP+)-challenged PC12 cells and primary neuronal midbrain cultures, as well as in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease. Substantial protection was found against MPP+-induced dopaminergic cell death in vitro. Moreover, subcutaneous application of G-CSF at a dose of 40 mu g/Kg body weight daily over 13 days rescued dopaminergic substantia nigra neurons from MPTP-induced death in aged mice, as shown by quantification of tyrosine hydroxylase-positive substantia nigra cells. Using HPLC, a corresponding reduction in striatal dopamine depletion after MPTP application was observed in G-CSF-treated mice. Thus our data suggest that G-CSF is a novel therapeutic opportunity for the treatment of Parkinson's disease, because it is well-tolerated and already approved for the treatment of neutropenic conditions in humans.
Issue Date
Journal of Neurochemistry 



Social Media